Fig. 4: In the Latin America cohort, vaccine efficacy (VE) against the primary COVID-19 endpoint by the SARS-CoV-2 antibody-escape score.
From: Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features
VE (point estimates as solid line, 95% confidence intervals as dashed lines) is shown by the antibody-escape scores for a DMS2, b PDB7, c PDB8, and d PDB13. In each panel, the “Double 1-sided unadjusted sieve p value” doubles the p value from a one-sided Wald test of the null hypothesis of constant VE vs. the alternative hypothesis of a decreasing VE with an increasing value of the feature on the x-axis (Juraska and Gilbert19, Section 5). The plot at the top of each panel shows the reverse cumulative distribution function (RCDF) of the relevant antibody-binding escape score across SARS-CoV-2 isolates by treatment arm: Vaccine, pink; Placebo, turquoise. CI confidence interval, DMS deep mutational scanning, FWER family-wise error rate, PDB Protein Data Bank, Unadj. unadjusted.
